Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Myomo, Inc.
ASCO Preview: Three Chinese Biotechs To Watch
BeiGene, Ascentage Pharma and I-Mab will be among the first Chinese pharma firms to report clinical trial results for their innovative drug candidates at this year’s ASCO meeting.
Gazyva, Imfinzi Launched Following Japan Listing, Entyvio In The Wings
Japan has granted reimbursement prices to two anticancer antibodies and other products as it supports the availability of new, higher priced therapies in areas of high medical need, including through early access, while Takeda’s Entyvio is also set for launch.
Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication
Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.
Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
- Rehabilitation Equipment and Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.